



## **Graftys granted key U.S. patent for GRFT-R02, a highly osteogenic biomaterial**

**Aix-en-Provence, July 6, 2016** - Graftys SA, a French medical device company specialized in the development, manufacturing and commercialization of synthetic orthopedic biomaterials, announced today that the U.S. Patent Office has granted US patent 13/923,577. This granted application covers an innovative, osteogenic biomaterial for bone tissue regeneration. This is the 8<sup>th</sup> patent granted to the company or to its licensors. It results from a large and ambitious collaboration between Graftys and the University of Nice, France, and the CNRS UMR 6235. Based on the priority date, the patent protection should last until 2028.

Jean-Marc Ferrier, Graftys Vice President Business Development, commented: “GRFT-R02 is a unique and highly osteogenic putty. This biomaterial is expected to allow surgeons to address difficult surgical situations like acetabular reconstruction, spinal fusion, non-union and complex cases of fracture healing with poor vascularization. GRFT-R02 showed impressive osteo-inductive properties in preclinical models with enhanced bone regeneration and was able to repair critical segmental bone defects in animal models. This biomaterial has a unique position among existing osteogenic bone graft solutions: it demonstrated similar efficacy to autograft, the current gold standard, in preclinical studies and is expected to exhibit a better safety profile compared to bone morphogenetic proteins (BMP)-derived products”.

Gilles Alberici, acting Chief Executive Officer of Graftys, added: “This is excellent news for our company, as this patent granted in the US strengthens our position for one of Graftys’ strategic R&D projects. This innovative technology associating a synthetic component with autologous growth factors has proven to be highly osteogenic in animal models, and is expected to be particularly suitable for clinical applications in spinal fusion, a new strategic orientation for Graftys. This could be a significant advance among osteogenic bone graft materials since it provides increased safety with reduced risk of complication.”

### **About GRFT-R02**

GRFT-R02 is a highly osteogenic putty based on a combination of autologous whole blood and ceramic, with optimized handling characteristics. The ceramic contains BCP particles calibrated to optimize osteo-conduction and enriched with calcium ions to enhance clot formation. The formation of fibrin has demonstrated increased biologic and osteogenic activity in preclinical studies. Targeted clinical indications include large bone defects (acetabular reconstruction, osteotomies), non-union and posterolateral spine fusion. The performance of GRFT-R02 is comparable to bone autograft, the current standard of care, in animal models.

### **About Graftys SA**

Founded in 2005, Graftys is based in Aix-en-Provence and Nantes (France), with a US office in Chicago. The company develops, manufactures and markets synthetic bioactive orthopedic biomaterials. Graftys technologies provide innovative therapeutic products in bone tissue engineering for unmet medical needs. The company partners with leading research institutions in France and is the licensee or the co-owner of 8 patent families. Graftys has received FDA clearance for three 510(k) applications with its calcium phosphate materials, which are also CE marked. Graftys products address various indications in orthopedics, traumatology, spine and dental. Graftys markets its range of products in over 25 countries, including the United States, through distribution partnerships.

For further information: <http://www.graftys.com>

Contact: [news@graftys.fr](mailto:news@graftys.fr)